145 related articles for article (PubMed ID: 15175539)
21. Cost effectiveness of varenicline versus bupropion and unaided cessation for smoking cessation in a cohort of Finnish adult smokers.
Linden K; Jormanainen V; Linna M; Sintonen H; Wilson K; Kotomäki T
Curr Med Res Opin; 2010 Mar; 26(3):549-60. PubMed ID: 20050814
[TBL] [Abstract][Full Text] [Related]
22. Crossing borders: factors affecting differences in cost-effectiveness of smoking cessation interventions between European countries.
Vemer P; Rutten-van Mölken MP
Value Health; 2010; 13(2):230-41. PubMed ID: 19804435
[TBL] [Abstract][Full Text] [Related]
23. Cost-effectiveness of different combinations of bupropion SR dose and behavioral treatment for smoking cessation: a societal perspective.
Javitz HS; Swan GE; Zbikowski SM; Curry SJ; McAfee TA; Decker DL; Patterson R; Jack LM
Am J Manag Care; 2004 Mar; 10(3):217-26. PubMed ID: 15032259
[TBL] [Abstract][Full Text] [Related]
24. Varenicline as compared to bupropion in smoking-cessation therapy--cost-utility results for Sweden 2003.
Bolin K; Mörk AC; Willers S; Lindgren B
Respir Med; 2008 May; 102(5):699-710. PubMed ID: 18289839
[TBL] [Abstract][Full Text] [Related]
25. The cost effectiveness of telephone counselling to aid smoking cessation in Denmark: a modelling study.
Rasmussen SR
Scand J Public Health; 2013 Feb; 41(1):4-10. PubMed ID: 23160318
[TBL] [Abstract][Full Text] [Related]
26. Smoking cessation in a blue-collar population: results from an evidence-based pilot program.
Ringen K; Anderson N; McAfee T; Zbikowski SM; Fales D
Am J Ind Med; 2002 Nov; 42(5):367-77. PubMed ID: 12382249
[TBL] [Abstract][Full Text] [Related]
27. Cost-benefit analysis of sustained-release bupropion, nicotine patch, or both for smoking cessation.
Nielsen K; Fiore MC
Prev Med; 2000 Mar; 30(3):209-16. PubMed ID: 10684744
[TBL] [Abstract][Full Text] [Related]
28. An evaluation of usage patterns, effectiveness and cost of the national smoking cessation quitline in Thailand.
Meeyai A; Yunibhand J; Punkrajang P; Pitayarangsarit S
Tob Control; 2015 Sep; 24(5):481-8. PubMed ID: 24920575
[TBL] [Abstract][Full Text] [Related]
29. Cost-effectiveness analysis of treatments to reduce cholesterol levels, blood pressure and smoking for the prevention of coronary heart disease: evaluative study carried out in Spain.
Plans-Rubió P
Pharmacoeconomics; 1998 May; 13(5 Pt 2):623-43. PubMed ID: 17165328
[TBL] [Abstract][Full Text] [Related]
30. Modelling a budgetary impact analysis for funding drug-based smoking cessation therapies for patients with major depressive disorder in Spain.
Rejas-Gutiérrez J; Bruguera E; Cedillo S
Eur Psychiatry; 2017 Sep; 45():41-49. PubMed ID: 28728094
[TBL] [Abstract][Full Text] [Related]
31. [Cost-Effectiveness of Pharmacological Smoking Cessation Therapies - A Systematic Literature Review].
Aumann I; Rozanski K; Damm K; Graf von der Schulenburg JM
Gesundheitswesen; 2016 Oct; 78(10):660-671. PubMed ID: 27784123
[No Abstract] [Full Text] [Related]
32. Cost-effective primary care-based strategies to improve smoking cessation: more value for money.
Salize HJ; Merkel S; Reinhard I; Twardella D; Mann K; Brenner H
Arch Intern Med; 2009 Feb; 169(3):230-5; discussion 235-6. PubMed ID: 19204212
[TBL] [Abstract][Full Text] [Related]
33. Cost and effectiveness of the nationwide government-supported Smoking Cessation Clinics in the Republic of Korea.
Oh JK; Lim MK; Yun EH; Shin SH; Park EY; Park EC
Tob Control; 2013 May; 22(e1):e73-7. PubMed ID: 22752272
[TBL] [Abstract][Full Text] [Related]
34. Nicotine replacement therapy for smoking cessation.
Silagy C; Mant D; Fowler G; Lancaster T
Cochrane Database Syst Rev; 2000; (2):CD000146. PubMed ID: 10796494
[TBL] [Abstract][Full Text] [Related]
35. Budgetary impact analysis on funding smoking-cessation drugs in patients with COPD in Spain.
Jiménez-Ruiz CA; Solano-Reina S; Signes-Costa J; de Higes-Martinez E; Granda-Orive JI; Lorza-Blasco JJ; Riesco-Miranda JA; Altet-Gomez N; Barrueco M; Oyagüez I; Rejas J;
Int J Chron Obstruct Pulmon Dis; 2015; 10():2027-36. PubMed ID: 26451100
[TBL] [Abstract][Full Text] [Related]
36. The cost-effectiveness of call-back counselling for smoking cessation.
Lal A; Mihalopoulos C; Wallace A; Vos T
Tob Control; 2014 Sep; 23(5):437-42. PubMed ID: 23748188
[TBL] [Abstract][Full Text] [Related]
37. Modeling the cost-effectiveness of a smoking-cessation program in a community pharmacy practice.
Tran MT; Holdford DA; Kennedy DT; Small RE
Pharmacotherapy; 2002 Dec; 22(12):1623-31. PubMed ID: 12495172
[TBL] [Abstract][Full Text] [Related]
38. Cost analysis of varenicline versus bupropion, nicotine replacement therapy, and unaided cessation in Nicaragua.
Lutz MA; Lovato P; Cuesta G
Hosp Pract (1995); 2012 Feb; 40(1):35-43. PubMed ID: 22406881
[TBL] [Abstract][Full Text] [Related]
39. Cost effectiveness of full coverage of the medical management of smoking cessation in France.
Chevreul K; Cadier B; Durand-Zaleski I; Chan E; Thomas D
Tob Control; 2014 May; 23(3):223-30. PubMed ID: 23197369
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
